Diabetes has long been one of the main diseases for which human embryonic stem cell (embryo-destroying) research, or hESCR, was claimed to hold the greatest promise of curing.

But for well over a decade now, ethically contentious human embryonic stem cell research (hESCR) has notably failed to live up to all its hype, with promises of miracle cures within “five to 10 years” remaining unfulfilled.

That remains true today, despite all the renewed hype that accompanied recent reports that researchers had coaxed hESCs into becoming insulin-producing cells.